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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Interferon (IFN) is able to induce significant psychiatric side effects in
chronic hepatitis C (CHC) patients, whereas the risk of nonpsychotic mental disorder (NPMD)
development in antiviral-treated mentally healthy CHC patients remains obscure. We used a
population-based study to assess the risk of NPMD development in patients who had undergone
antiviral treatment compared with untreated chronic hepatitis C virus (HCV)-infected and
nonalcoholic fatty liver disease (NAFLD) patients.
Methods: Data were retrieved from Taiwan’s National Health Insurance Research Database
cohort consisting of 1 million individuals for a longitudinal analysis. A total of 313 mentally
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830 S.-C. Chang et al.with those without antiviral therapy and NAFLD patients. The Chi-square test was used to
obtain the hazard ratio and 95% confidence interval.
Results: Among the 313 CHC patients receiving pegylated interferon/ribavirin therapy, 62 pa-
tients (19.8%) were associated with NPMD. In the comparison cohort, composed of 313 age- and
sex-matched CHC patients not receiving antiviral therapy, 70 patients (22.4%) were associated
with NPMD. The Chi-square analysis revealed that antiviral therapy was not significantly asso-
ciated with NPMD. The diagnosis of HCV-infected hepatitis was independently associated with
NPMD when compared with NAFLD. The hazard ratio was 1.67 (95% confidence interval, 1.11
e2.52; p Z 0.018). Furthermore, generalized anxiety disorder was specifically higher in
HCV-infected patients than those with NAFLD.
Conclusion: Patients with HCV infection are at high risk of developing NPMD with or without
IFN-based therapy.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
It has been estimated that 170 million people worldwide
are chronic carriers of hepatitis C virus (HCV). Nosocomial
infection, blood transfusion, and injection are considered
major risk factors. HCV infection frequently causes chronic
liver disease leading to cirrhosis and hepatocellular carci-
noma (HCC).1,2 The current standard-of-care (SOC) therapy
for HCV infection involves a combination of pegylated
interferon-a (PEG-IFN-a) and ribavirin (RBV). PEG-IFN-a is a
chemically modified recombinant interferon (IFN) with an
additional molecule of polyethylene glycol, which increases
its half-life and improves antiviral efficiency.3 The combi-
nation of PEG-IFN-a and RBV increased the rate of viral
response from 10% to 50%,3 and reduced the 5-year cumu-
lative incidence of HCC by 7.8% in patients with hepatitis
C.2 However, PEG-IFN-a-based therapy appears to induce
significant psychiatric side effects, such as depression,
insomnia, fatigue, anxiety, cognitive disturbance, or sui-
cide attempts (the worst complication of severe depressive
syndrome), in patients with chronic hepatitis C (CHC).4
In some instances, psychiatric side effects are the main
reason for the termination of antiviral therapy.5,6 One study
showed that some patients may delay or refuse treatment
because of psychiatric morbidities,7 and strategies such as
cautious monitoring with early intervention or preemptive
antidepressant treatment for CHC patients with preexisting
mental health problems to ameliorate its impact have been
reported.8 By contrast, Pavlovic et al9 showed that lifetime
psychiatric disorders in CHC patients were not significantly
associated with depressive syndrome in PEG-IFN-a therapy,
indicating that IFN-a therapy is safe for CHC patients, even
those with preexisting mental disorders. And by an inter-
disciplinary treatment setting, psychiatric diseases and/or
drug addiction did not negatively influence the psychiatric
tolerability of and antiviral treatment response to PEG-IFN-
a plus RBV.10
Given that the depressive syndrome seems to prevail
among CHC patients receiving PEG-IFN-a plus RBV therapy
especially those with preexisting mental disorders, the risk
of nonpsychotic mental disorder (NPMD) development in
mentally healthy CHC patients during current SOC was
rarely reported. To assess this issue, a population-based,
longitudinal survey is required. Taiwan’s National Health
Insurance Research Database (NHIRD) was derived from thecountry’s National Health Insurance (NHI) program and
maintained by the Taiwan National Health Research Insti-
tute (NHRI). Each year, the NHRI collects data from the NHI
program and classifies them into the NHIRD. In 2008, 22.89
million of the country’s 22.96 million people (up to 99.7% of
the Taiwan’s population) were covered by the NHI pro-
gram.11 More than 300 studies have been published in peer-
reviewed journals based on the NHIRD. This study sought to
determine the incidence and risk of NPMDs among CHC
patients without a history of mental health problems who
were receiving PEG-IFN-a plus RBV therapy from the NHIRD.Methods
Study population
The Taiwan Bureau of National Health Insurance (BNHI)
provided electronic data, which included patients’ sex,
birthday, the classification code of the diseases diagnosed,
data of health services received, and the clinic or hospital
code. Each year, the Taiwan NHRI collects data from the
NHI program and sorts it into data files, including registra-
tion files and original claim data for reimbursement. These
data files are deidentified by scrambling the identification
codes of both patients and medical facilities and sent to the
NHRI to form the original files of NHIRD. Data used in this
study were retrieved from the representative NHIRD cohort
from September 2006 to December 2010 consisting of 1
million individuals for longitudinal study (subtracting 1 in 20
NHI beneficiaries). Individuals with duplicate files or
incomplete information were excluded from the data ana-
lyses. Access of the NHIRD has been approved by the NHRI
Ethics Review Committee.
A total of 5568 cases (2270 were male, 2798 female) that
met the CHC diagnostic criteria (as shown below) were
selected. Of the total, we excluded 1182 cases because
these individuals had either HCC or NPMD diagnosis in the
past 1 year. Overall, 4386 cases (2280 male and 2106 fe-
male) were further analyzed, of which 340 received anti-
viral therapy and the others (4046 cases) did not receive
any antiviral treatment. Of the 340 recruited antiviral-
treated CHC patients, 27 were excluded owing to a coex-
isting NAFLD (nonalcoholic fatty liver disease) diagnosis,
which left a final total of 313 patients to analyze (as shown
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female) met the diagnostic criteria as shown below, of
which 381 individuals were excluded because they had a
history of HCC or NPMD diagnosed in the past 1 year. Thus, a
total of 2095 NAFLD cases (male 1293 and female 802) were
selected for further analysis. By controlling for age and sex
using a propensity score less than 0.001, we randomly
recruited 313 patients for each three groups in the end. All
CHC patients were confirmed by two follow-up ambulatory
care visits or hospitalization for hepatitis C from the
2006e2010 reimbursement claims data of the NHIRD. The
incidence rate of NPMD for patients treated with PEG-IFN-a
plus RBV during a 12-month follow-up period was compared
to that of patients with CHC who were not treated with
PEG-IFN-a and RBV during the same period. For each pa-
tient treated with PEG-IFN-a and RBV, one hepatitis C pa-
tient who did not receive antiviral treatment matched for
age and sex was randomly identified as part of the refer-
ence group.
Definition
Cases of CHC were identified from the NHIRD from year
2006 to 2010 using the 9th revision of the International
Classification of Diseases, Clinical Modification (ICD-9-CM).
We have excluded adjustment reaction with liver carci-
noma (ICD-9-CM code 155.0) and preexisting NPMDs (ICD-9-
CM code 296.2, 296.3, 311, 300.XX). CHC was defined as
patients diagnosed with either ICD-9-CM code betweenSubjects who met CHC diagnostic 
criteria by ICD-9-CM (who visited 
clinic more than two occasions
within 7 months) , 2006 –2009.
4,386 subjects (male 
2,280, female 2,106) were 
analyzed
340 subjects received 
antiviral therapy 
313 CHC subjects received 
PEG-IFN and/or RBV therapy were 
recruited for study group
Excluded subjects with 
ICD-9-CM diagnosis of 
HCC or NPMD in the 
previous one year before 
their first CHC clinic visit 
Subjects who did not 
receive antiviral therapy 
(medication codes ATC 
No: L03AB11 and/or 
ATC No: J50AB04) were 
excluded (N=4,046)
Excluded subjects who 
also had NAFLD
(nonalcoholic fatty liver 
disease) (N=27)
Figure 1 Patient selection flow chart for CHC patients who
received antiviral therapy. CHC Z chronic hepatitis C.070.41, 070.44, 070.51, 070.54, 070.70, and V02.62 at least
twice beyond a consecutive period of 6 months. The iden-
tified patients treated with IFN (ATC No: L03AB11) and/or
RBV (ATC No: J50AB04) were defined as CHC patients
receiving antiviral therapy. The NPMDs include: (1) major
depressive disorders (MDDs; ICD-9-CM code 296.2, 296.3,
311) and neurotic depression (ICD-9-CM code 300.04); (2)
generalized anxiety disorders (ICD-9-CM code 300, 300.0,
300.00, 300.02, 300.2); and (3) panic disorders (ICD-9-CM
code 300.01, 300.21, 300.22), with any identifiable afore-
mentioned diagnostic codes at least once at a time after a
diagnosis of CHC or NAFLD for each selected participants.
NAFLD (ICD-9-CM code 571.8), with obtainable diagnostic
code at least twice beyond 6 months, thoroughly excluded
hepatitis B virus and HCV diagnosis, was included in this
study as control.
Statistical analysis
We first calculated the overall incidence of NPMDs for the
two study groups. The annual incidence was the number of
new cases that developed NPMD divided by the size of the
population with hepatitis C in each year. The annual inci-
dence of NPMDs was calculated for the study group (CHC
treated with PEG-IFN-a plus RBV)/reference group (CHC not
treated with PEG-IFN-a and RBV) risk ratios presented as
odds ratio and 95% confidence interval (CI). The Chi-square
test was used to obtain the odds ratio and 95% CI. In the
data analysis, we further compared the average age-
specific incidences in the 4-year period between the two
groups.
Results
The mean age for the 626 sampled individuals was
52.5  11.11 years. Table 1 shows the distributions of de-
mographic characteristics of the CHC patients with or
without antiviral therapy after matching for age and sex.
Demographically, there was neither any significant differ-
ence in monthly income and geographic regions (northern,
central, eastern, and southern Taiwan) between patients
with and without antiviral therapy. Table 2 shows that CHC
patients with antiviral therapy did not have a higher prev-
alence of NPMDs (19.8% vs. 22.4%; p > 0.05) when
compared with CHC patients without antiviral therapy. The
hazard ratio was 0.86 (95% CI, 0.58e1.26; p > 0.05).
Because CHC patients had a higher prevalence of depres-
sive disorders, we compared the incidence of NPMDs with
that of NAFLD. Table 3 shows that CHC patients without
antiviral therapy had a higher prevalence when compared
with NAFLD patients (8.7% vs. 5.5%; p < 0.02); the hazard
ratio was 1.67 (95% CI 1.11e2.52; p < 0.02).
To delineate which NPMD is most prevalent in hepatitis C
patients, we examined the incidence of overall NPMDs
including: (1) MDDs (ICD-9-CM code 296.2, 296.3, 311) and
neurotic depression (ICD-9-CM code 300.04); (2) general-
ized anxiety disorders (ICD-9-CM code 300, 300.0, 300.00,
300.02, 300.2); and (3) panic disorders (ICD-9-CM code
300.01, 300.21, 300.22). Table 4 shows that among the 313
CHC patients receiving antiviral therapy, 3.5% developed
MDD, 17.9% developed generalized anxiety disorder and
Table 1 Demographic characteristics of CHC patients.
Variables Antiviral-treated
CHC patients N (%)
Untreated CHC
Patients N (%)
p
Sex
Male 183 (58.5) 183 (58.5) > 0.99
Female 130 (41.5) 130 (41.5)
Age (y)
40 47 (15.0) 47 (15.0) > 0.99
41e50 74 (23.6) 74 (23.6)
51e60 131 (41.9) 131 (41.9)
61e80 61 (19.5) 61 (19.5)
Occupation
Employed 265 (84.7) 266 (85.0) > 0.99
Unemployed 48 (15.3) 47 (15.0)
CHC Z chronic hepatitis C.
Table 3 Demographic characteristics and crude hazard
ratios for NPMD among the untreated CHC and NAFLD
patients.
Variables Untreated
CHC patients
Nonalcoholic
fatty liver
disease
patients
p
Sex
Male 183 (58.5) 183 (58.5) > 0.99
Female 130 (41.5) 130 (41.5)
Age (y)
 40 47 (15.0) 47 (15.0) > 0.99
41e50 74 (23.6) 74 (23.6)
51e60 131 (41.9) 131 (41.9)
61e80 61 (19.5) 61 (19.5)
Occupation
Employed 266 (85.0) 255 (81.5) > 0.99
Unemployed 47 (15.0) 58 (18.5)
Presence of NPMD
Yes 70 (22.4) 46 (14.7)
No 243 (77.6) 267 (85.3)
Hazard ratios
(95% CI)
1.67 (1.11e2.52) 0.018
Data are presented as N (%).
CHCZ chronic hepatitis C; CIZ confidence interval; NAFLDZ
nonalcoholic fatty liver disease; NPMD Z nonpsychotic mental
disorder.
832 S.-C. Chang et al.2.2% developed panic disorder, which were not significantly
different from those without antiviral therapy. Noticeably,
there were 17.9% hepatitis C patients with antiviral therapy
and 20.4% hepatitis C patients without antiviral therapy
who developed a generalized anxiety disorder. When
compared to NAFLD patients (14.1% presented with gener-
alized anxiety disorder), CHC patients were specifically
associated with generalized anxiety disorders (hazard
ratio Z 1.57, 95% CI 1.03e2.39).Discussion
Depression and anxiety in patients with chronic HCV
infection have been shown to be correlated to antiviral
treatment.12 Most of these surveys used depression rating
scales as measurement tools. Although the screening tools
are reliable, valid, and useful screening instruments to
detect NPMD in CHC patients receiving antiviral therapy,
they have several limitations: relatively small sample size,
absence of patients with CHC who did not receive antiviral
therapy for comparison, and the study period is usually
limited.13 Reports on physician-diagnosed incidence of
NPMDs with a population-based sample for hepatitis C pa-
tients are limited in the literature. The strength of this
study is that all hepatitis C patients in Taiwan were
included. The NHI in Taiwan is a mandatory enrollment
universal health insurance program with a coverage rate of
higher than 96%.14 The randomly selected references in this
study make the measurement of incidence reliable and
similar to using the whole population as the denominator.Table 2 Crude hazard ratios for NPMD among the CHC patients
Presence of
NPMD
Total sample
(N Z 626)
Antiviral-treated
CHC patients N (%
Yes 132 (21.1) 62 (19.8)
No 494 (78.9) 251 (80.2)
CHC Z chronic hepatitis C; CI Z confidence interval; NPMD Z nonpsThus, selection bias was substantially reduced. To our
knowledge, no previous studies have used nationwide
health insurance data to investigate NPMD for CHC patients
in Taiwan.
PEG-IFN-a treatment-associated depressive disorders
have been shown in renal cell cancer,15 chronic myeloid
leukemia,16 and malignant melanoma.17 However, our re-
sults showed that the incidence rate of NPMD was 19.8% for
patients with antiviral therapy and 22.4% for patients
without antiviral therapy. MDD was 3.5% in CHC patients
receiving antiviral therapy, which was not different from
those without antiviral therapy (2.9%). Our results are
different from those of Nomura et al,18 who showed that
administration of IFN-b/RBV was associated with a lower
incidence of depression symptom development during
treatment compared to patients who were treated with
PEG-IFN-a plus RBV. However, in patients already diagnosed
with depression, there was no evidence that PEG-IFN-a plus
RBV therapy caused any worsening of symptoms, indicating.
)
Untreated CHC
patients N (%)
Hazard ratios (95% CI)
70 (22.4) 0.86 (0.58e1.26)
243 (77.6)
ychotic mental disorder.
Table 4 Crude hazard ratios for NPMD among the CHC and NAFLD patients.
Presence of NPMD Total sample
(N Z 939)
Antiviral-treated
CHC patients
(N Z 313) A
Untreated
CHC patients
(N Z 313) B
Nonalcoholic
fatty liver
disease
patients
(N Z 313) C
Hazard ratios
(95% CI) A:B
Hazard ratios
(95% CI) B:C
More than one
diagnosis
Yes 178 (19.0) 62 (19.8) 70 (22.4) 46 (14.7) 0.86 1.67*
No 761 (81.0) 251 (80.2) 243 (77.6) 267 (85.3) 0.58e1.26 1.11e2.52
1. Major depressive
disorders
Yes 24 (2.6) 11 (3.5) 9 (2.9) 4 (1.3) 1.23 2.29
No 915 (97.4) 302 (96.5) 304 (97.1) 309 (98.7) 0.50e3.01 0.70e7.49
2. Generalized anxiety
disorders
Yes 164 (17.5) 56 (17.9) 64 (20.4) 44 (14.1) 0.85 1.57*
No 775 (82.5) 257 (82.1) 249 (79.6) 269 (85.9) 0.57e1.26 1.03e2.39
3. Panic disorders Yes 18 (1.9) 7 (2.2) 9 (2.9) 2 (0.6) 0.77 4.60
No 921 (98.1) 306 (97.8) 304 (97.1) 311 (99.4) 0.28e2.10 0.99e21.43
Data are presented as N (%).
*p < 0.05.
CHCZ chronic hepatitis C; CIZ confidence interval; NAFLDZ nonalcoholic fatty liver disease; NPMDZ nonpsychotic mental disorder.
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therapy is safe for CHC patients with depression.18 Simi-
larly, Spennati and Pariante (2012) reviewed 14 studies that
have administered IFN-a to patients with a preexisting
psychiatric disorder; they found that IFN-a-induced psy-
chiatric symptoms responded successfully to clinical man-
agement and concluded that there is no support to
withdrawing IFN-a therapy from patients with preexisting
psychiatric disorders.19 Meanwhile, a European expert
consensus statement reported in 2012 that antidepressant
pretreatment is not generally recommended for all CHC
patients during antiviral therapy, which should be based on
a “case by case decision and patient’s view.”20
The reasons that mentally healthy CHC patients had a
lower incidence of NPMD development in response to PEG-
IFN-a plus RBV therapy were not clear. Possible explana-
tions include the relatively high baseline prevalence of
depressive symptoms in overall CHC patients, and patients
who were willing to receive current SOC are prone to have a
positive attitude regarding their diseases. And because
most diagnostic manuals of psychiatric disorders require
that the symptoms and/or functional impairment be pre-
sent for more than a few weeks, an actual diagnosis is
difficult to establish when patients develop symptoms of
depression or anxiety during antiviral therapy. We showed
that CHC patients were susceptible to MDD when compared
to NAFLD patients. These results are consistent with those
of Carta et al,21 who found that MDDdsimilar to recurrent
brief depressiondwas the most prevalent subtype of af-
fective depressive disorders among CHC patients. Indeed,
depressive syndromes, including recurrent brief depres-
sion, have frequently been observed in association with
chronic diseases characterized by immune activation, such
as autoimmune thyroiditis or celiac disease.21 The present
study supports the observation that chronic HCV infection is
associated with MDD development irrespective of PEG-IFN-
a plus RBV therapy.22
This study has several potential limitations. First, some
clinically relevant patient and lifestyle informationdsuch
as smoking status, alcohol consumption and dietary habits,
body mass index, and pharmaceutical use, all of which maycontribute to these two conditionsdwas not available
through the administrative dataset. Second, although it is
strongly supported that the vast majority of hepatitis C
cases were genotype 1, the identification of viral genotype
was not included in the population-based dataset and could
not be included in this study. Third, the determination of
HCV RNA that confirmed the patient’s infection status was
not available in the claimed dataset. Fourth, the risk of
depressive disorders may vary with the severity of the
depression; however, the severity of depressive disorders
was not included in the population-based dataset and
therefore could not be included in this study. Fifth, it is
highly possible that a certain portion of CHC patients with a
mild degree of NPMD were underdiagnosed by hepatologists
because of their inexperience in approaching neuropsychi-
atric symptoms. Sixth, the disease severity of NAFLD could
not be ascertained from the dataset, and it should be noted
that there had been one recent report that demonstrated a
positive correlation between depression and severity of
hepatocyte ballooning in NAFLD patients.23 And finally,
because of database limitations, patients’ comorbidity and
liver disease severity could not be included for analysis.
In conclusion, this study demonstrates that mentally
healthy CHC patients in Taiwan are at high risk of devel-
oping NPMD with or without IFN-based antiviral therapy.
Thorough psychiatric evaluation plays an important role in
the delivery of quality health care in CHC patients regard-
less of whether or not they were treated with IFN-based
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